Androgen receptor in salivary gland carcinoma: A review of an old marker as a possible new target | Zendy

Yeoh Chit Cheng | Zendy; Dabab Nedal | Zendy; Rigby Elyse | Zendy; Chhikara Ritu | Zendy; Akaev Iolia | Zendy; Gomez Ricardo Santiago | Zendy; Fonseca Felipe | Zendy; Brennan Peter A. | Zendy; Rahimi Siavash | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Androgen receptor in salivary gland carcinoma: A review of an old marker as a possible new target

Author(s) -

Yeoh Chit Cheng,

Dabab Nedal,

Rigby Elyse,

Chhikara Ritu,

Akaev Iolia,

Gomez Ricardo Santiago,

Fonseca Felipe,

Brennan Peter A.,

Rahimi Siavash

Publication year - 2018

Publication title -

journal of oral pathology and medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.887

H-Index - 83

eISSN - 1600-0714

pISSN - 0904-2512

DOI - 10.1111/jop.12741

Subject(s) - androgen receptor , salivary duct carcinoma , salivary gland , medicine , androgen , head and neck , cancer research , receptor , carcinoma , endocrinology , oncology , cancer , hormone , prostate cancer , surgery

The role of the androgen receptor ( AR ) as an immunomarker for diagnosis of salivary gland duct carcinoma ( SDC ) is well known. Other non‐squamous cell head and neck cancers ( NSCC ‐ HN ), including a small subset of salivary gland cancers ( SGC s), can also express AR . With the increase in effective and powerful new generation of anti‐androgen agents and drugs administered orally, more targetable AR ‐driven NSCC ‐ HN , such as subsets of SGC s, should be investigated for possible expression of AR . In this review, we focus on SGC subtypes, which could express AR and describe the main androgen deprivation therapy ( ADT ) strategies.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research